Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.

被引：0
|
作者：
West, H
Belt, RJ
Wakelee, HA
Bloss, LP
Taylor, L
Monberg, MJ
Ye, Z
Obasaju, CK
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Kansas City Canc Ctr, Kansas City, MO USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：649S / 649S
页数：1
相关论文
共 50 条
  • [21] Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    Stathopoulos, G. P.
    Katis, C.
    Tsavdaridis, D.
    Dimitroulis, J.
    Karaindros, D.
    Stathopoulos, J.
    Dimou, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 555 - 560
  • [22] Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Kaiser, Christopher
    Biesma, Bonne
    Manegold, Christian
    Gatzemeier, Ulrich
    Serwatowski, Piotr
    Syrigos, Kostas
    Balint, Beatrix
    Smit, Hans J.
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S375 - S375
  • [23] Multi-institutional phase II study of docetaxel (D) and gemcitabine (G) as front-line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Amenedo, M
    Mel, JR
    Casal, J
    Rodriguez, MR
    Aparicio, LA
    Constenla, M
    Lopez, R
    Almanza, C
    Huarte, L
    ANNALS OF ONCOLOGY, 2000, 11 : 112 - 112
  • [24] Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer
    Isla, D
    Rosell, R
    Sánchez, JJ
    Carrato, A
    Felip, E
    Camps, C
    Artal, A
    González-Larriba, JL
    Azagra, P
    Alberola, J
    Martin, C
    Massutí, B
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 1071 - 1077
  • [25] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
    Kouroussis, C
    Syrigos, K
    Potamianou, A
    Ziras, N
    Ziotopoulos, P
    Stergiou, J
    Ginopoulos, P
    Tselepatiotis, E
    Biozionelou, V
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S
  • [26] A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Tamiya, Akihiro
    Morimoto, Masahiro
    Fukuda, Shoichi
    Naoki, Yoko
    Ibe, Tatsuya
    Okishio, Kyoichi
    Goto, Hideto
    Yoshii, Akihiro
    Kita, Toshiyuki
    Nogami, Naoyuki
    Fujita, Yuka
    Atagi, Shinji
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 667 - 673
  • [27] A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer
    Akihiro Tamiya
    Masahiro Morimoto
    Shoichi Fukuda
    Yoko Naoki
    Tatsuya Ibe
    Kyoichi Okishio
    Hideto Goto
    Akihiro Yoshii
    Toshiyuki Kita
    Naoyuki Nogami
    Yuka Fujita
    Shinji Atagi
    Investigational New Drugs, 2018, 36 : 667 - 673
  • [28] Gemcitabine in locally advanced and metastatic non-small cell lung cancer (NSCLC): The Central European phase II study
    Jassem, J
    Zatloukal, P
    Kanitz, E
    Magyar, P
    Krzakowski, M
    Pawlicki, M
    Petruzelka, L
    Chovan, L
    Pesek, M
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [29] A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).
    Simon, G. R.
    Janne, P. A.
    Langer, C.
    Clarie, V.
    Dowlati, A.
    Gadgeel, S. M.
    Kelly, K.
    Ye, Z.
    Obasaju, C. K.
    Hood, K. E.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
  • [30] Phase II trial of gemcitabine (G), carboplatin (C) and bexarotene (B) in patients (pts) with newly diagnosed, locally-advanced or metastatic non-small cell carcinoma of the lung (NSCLC).
    Estephan, FF
    Hasham-Jiwa, N
    Klementich, F
    Logrono, R
    Eltorky, M
    Bhutani, M
    Walser, E
    Zwischenberger, J
    Kessel, I
    Jones, DV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 697S - 697S
12345